DK1370243T3 - Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor - Google Patents

Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor

Info

Publication number
DK1370243T3
DK1370243T3 DK02701872T DK02701872T DK1370243T3 DK 1370243 T3 DK1370243 T3 DK 1370243T3 DK 02701872 T DK02701872 T DK 02701872T DK 02701872 T DK02701872 T DK 02701872T DK 1370243 T3 DK1370243 T3 DK 1370243T3
Authority
DK
Denmark
Prior art keywords
sup
microparticles containing
atpase inhibitor
obtaining microparticles
atp
Prior art date
Application number
DK02701872T
Other languages
English (en)
Inventor
Hakan Glad
Malin Soederbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1370243T3 publication Critical patent/DK1370243T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
DK02701872T 2001-03-09 2002-03-06 Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor DK1370243T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Publications (1)

Publication Number Publication Date
DK1370243T3 true DK1370243T3 (da) 2008-10-13

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02701872T DK1370243T3 (da) 2001-03-09 2002-03-06 Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor

Country Status (22)

Country Link
US (2) US20040101565A1 (da)
EP (1) EP1370243B1 (da)
JP (1) JP2004522796A (da)
KR (1) KR20030081506A (da)
CN (1) CN1507343A (da)
AT (1) ATE400253T1 (da)
AU (1) AU2002235101B8 (da)
BR (1) BR0207827A (da)
CA (1) CA2440163A1 (da)
DE (1) DE60227488D1 (da)
DK (1) DK1370243T3 (da)
ES (1) ES2307722T3 (da)
HK (1) HK1059896A1 (da)
IL (1) IL157467A0 (da)
MX (1) MXPA03007887A (da)
NO (1) NO20033966L (da)
NZ (1) NZ527997A (da)
PT (1) PT1370243E (da)
SE (1) SE0100822D0 (da)
SI (1) SI1370243T1 (da)
WO (1) WO2002072071A1 (da)
ZA (1) ZA200306614B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20070207266A1 (en) * 2006-02-15 2007-09-06 Lemke Harald K Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) * 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
WO1999018935A1 (de) * 1997-10-15 1999-04-22 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ES2362418T3 (es) * 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles

Also Published As

Publication number Publication date
US20040101565A1 (en) 2004-05-27
PT1370243E (pt) 2008-09-16
DE60227488D1 (de) 2008-08-21
KR20030081506A (ko) 2003-10-17
IL157467A0 (en) 2004-03-28
AU2002235101B2 (en) 2006-07-13
SE0100822D0 (sv) 2001-03-09
NO20033966L (no) 2003-11-03
NO20033966D0 (no) 2003-09-08
US20080175917A1 (en) 2008-07-24
WO2002072071A1 (en) 2002-09-19
NZ527997A (en) 2005-02-25
ZA200306614B (en) 2004-11-25
SI1370243T1 (sl) 2008-12-31
CA2440163A1 (en) 2002-09-19
HK1059896A1 (en) 2004-07-23
CN1507343A (zh) 2004-06-23
BR0207827A (pt) 2004-03-02
ES2307722T3 (es) 2008-12-01
EP1370243A1 (en) 2003-12-17
AU2002235101B8 (en) 2006-08-31
ATE400253T1 (de) 2008-07-15
MXPA03007887A (es) 2003-12-04
EP1370243B1 (en) 2008-07-09
JP2004522796A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
DK1370243T3 (da) Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor
IS2170B (is) Sýklópentanóindól, efnablöndur sem innihalda slíkefnasambönd og meðhöndlunaraðferðir
RS50360B (sr) Farmaceutske formulacije derivata platine
EP0931788A3 (en) Metalloprotease inhibitors
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
IS6218A (is) Lyfjasamsetning sem inniheldur fenófíbrat og aðferðir til framleiðslu á því
WO2003085513A3 (en) A software distribution method and system
BR0116969A (pt) método e sistema de gerenciamento de resìduo
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1558931A4 (en) ANALYSIS OF PHARMACEUTICAL SOLUBILITY AND STABILITY
NO20033967D0 (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
IL162314A (en) Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
ATE275401T1 (de) Herstellung von inogatran-agglomeraten und die verbindung inogatran-anhydrid
TH52877A3 (th) N-(3-เอททินิลฟีนิลามิโน)-6,7-บิส(2-เมททอกซีเอททอกซี)-4-ควินาโซลินเอมีนเมซิเลตแอนไฮเดรตและโมโนไฮเดรต
DE60209354D1 (de) Hydroxamsäure-derivate